ACRIVON THERAPEUTICS INC (ACRV) Stock News
NASDAQ:ACRV - Nasdaq - US0048901096 - Common Stock - Currency: USD
ACRV Latest News, Press Relases and Analysis
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent,...
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
– Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient selection...
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q2 2024
ACRV stock results show that Acrivon Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acrivon Therapeutics (NASDAQ:ACRV) just reported results for the second quarter...
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024
ACRV stock results show that Acrivon Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
AP3-identified clinical biomarkers for ACR-368 led to the development of a response-predictive OncoSignature assay which has shown statistically...
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage...
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
- First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316 - ACR-2316 was...
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with...
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage...
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage...
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage...
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a great way to start Thursday as we check out all of the hottest news moving shares this morning!
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
• Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative)...
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors,...
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0.46% to 38,713.72 while the NASDAQ fell 0.24% to 16,215.32. The S&P 500 also fell, dropping, 0.39% to 5,182.36.
Why Is Rail Vision (RVSN) Stock Up 17% Today?
Rail Vision stock is taking off on Tuesday as RVSN investors celebrate an order for its AI Switch Yard System from a Class 1 company.
ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost
Acrivon Therapeutics stock is up on Tuesday with heavy trading of ACRV shares alongside $130 million in new funding today.